Figure 12.

Network diagram of PD-L1-positive and -negative subgroups. (a-b) OS and PFS of patients with PD-L1 ≥ 1%; (c-d) OS and PFS of patients with PD-L1 < 1%. The dots in the figure represent different treatment methods; the size of the dots represents the sample size using that treatment; the line between the dots represents a direct comparison between the two treatments; the thickness of the line represents the number of studies. Atez: atezolizumab; Chem: chemotherapy; Nivo: nivolumab; Ipil: ipilimumab.